[Bone marrow megaloblastosis associated with the use of pyrimethamine, triamterene and trimethoprim-sulfamethoxazole].
D000328:Adult; D000368:Aged; D000748:Anemia, Macrocytic / Q000139:chemically induced*; D000749:Anemia, Megaloblastic / Q000139:chemically induced*; D001853:Bone Marrow / Q000473:pathology; D004338:Drug Combinations / Q000009:adverse effects; D005260:Female; D005493:Folic Acid Antagonists / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008534:Megaloblasts / Q000473:pathology; D008875:Middle Aged; D011739:Pyrimethamine / Q000009:adverse effects; D013420:Sulfamethoxazole / Q000009:adverse effects; D014223:Triamterene / Q000009:adverse effects; D014295:Trimethoprim / Q000009:adverse effects; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D005493:Folic Acid Antagonists; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D014223:Triamterene; D011739:Pyrimethamine
Megaloblastosis medular asociada al uso de pirimetamina, triamterene y trimetoprim-sulfametoxazol.